Hydroxychloroquine in systemic lupus erythematosus (SLE)
C Ponticelli, G Moroni - Expert opinion on drug safety, 2017 - Taylor & Francis
Introduction: Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that
accumulates in lysosomes where it inhibits some important functions by increasing the pH …
accumulates in lysosomes where it inhibits some important functions by increasing the pH …
Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis
R Giacomelli, A Afeltra, A Alunno, E Bartoloni-Bocci… - Autoimmunity …, 2019 - Elsevier
Autoimmune rheumatic diseases are characterised by an abnormal immune system
response, complement activation, cytokines dysregulation and inflammation. In last years …
response, complement activation, cytokines dysregulation and inflammation. In last years …
Antiphospholipid syndrome and the neurologist: from pathogenesis to therapy
T Fleetwood, R Cantello, C Comi - Frontiers in neurology, 2018 - frontiersin.org
Antiphospholipid syndrome (APS) is an autoimmune antibody-mediated condition
characterized by thrombotic events and/or pregnancy morbidity in association with persistent …
characterized by thrombotic events and/or pregnancy morbidity in association with persistent …
Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome
L Naranjo, L Stojanovich, A Djokovic… - Frontiers in …, 2022 - frontiersin.org
Background Antiphospholipid syndrome (APS) is a multisystemic autoimmune disorder
characterized by thrombotic events and/or gestational morbidity in patients with …
characterized by thrombotic events and/or gestational morbidity in patients with …
The treatment of anti-phospholipid syndrome: a comprehensive clinical approach
CB Chighizola, L Andreoli, M Gerosa, A Tincani… - Journal of …, 2018 - Elsevier
Anti-phospholipid syndrome (APS) is an acquired pro-thrombotic autoimmune disease that
predisposes to thrombotic events and/or obstetric complications, in the persistent presence …
predisposes to thrombotic events and/or obstetric complications, in the persistent presence …
Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications
F Tedesco, MO Borghi, M Gerosa… - Frontiers in …, 2018 - frontiersin.org
Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by
thromboembolic events, pregnancy morbidity, and the presence of antiphospholipid (aPL) …
thromboembolic events, pregnancy morbidity, and the presence of antiphospholipid (aPL) …
[HTML][HTML] New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats
P Durigutto, C Grossi, MO Borghi, P Macor… - …, 2019 - ncbi.nlm.nih.gov
Clinical studies have reported different diagnostic/predictive values of antibodies to domain
1 or 4/5 of β 2 glycoproteinI in terms of risk of thrombosis and pregnancy complications in …
1 or 4/5 of β 2 glycoproteinI in terms of risk of thrombosis and pregnancy complications in …
Incidence of thromboembolic events in asymptomatic carriers of IgA anti ss2 glycoprotein-I antibodies
C Tortosa, O Cabrera-Marante, M Serrano… - PLoS …, 2017 - journals.plos.org
Background The antiphospholipid syndrome (APS) is defined by simultaneous presence of
vascular clinical events and antiphospholipid antibodies (aPL). The aPL considered as …
vascular clinical events and antiphospholipid antibodies (aPL). The aPL considered as …
Clinical insights into diffuse alveolar hemorrhage in antiphospholipid syndrome
SA Stoots, L Lief, D Erkan - Current Rheumatology Reports, 2019 - Springer
Abstract Purpose of Review Diffuse alveolar hemorrhage (DAH) is a rare but devastating
manifestation of antiphospholipid syndrome (APS) patients with or without other systemic …
manifestation of antiphospholipid syndrome (APS) patients with or without other systemic …
Treatment of antiphospholipid syndrome beyond anticoagulation
C Dobrowolski, D Erkan - Clinical Immunology, 2019 - Elsevier
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder marked by thrombosis
and/or pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). At the …
and/or pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). At the …